Recombinant Human Tumor Necrosis Factor Produces Hemodynamic Changes Characteristic of Sepsis and Endotoxemia

Archives of Surgery

Volumn 124, Issue 4, 1989, Pages 445-448

  Schirmer, William J ^a,b   Schirmer, James M ^a   Fry, Donald E ^a,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT DNA; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ENDOTOXEMIA; GENETIC ENGINEERING; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; SHOCK;

ANIMAL; BACTERIAL INFECTIONS; BLOOD PRESSURE; CARDIAC OUTPUT; ENDOTOXINS; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; LIVER CIRCULATION; RATS; RATS, INBRED STRAINS; RECOMBINANT PROTEINS; RENAL CIRCULATION; SUPPORT, U.S. GOV'T, NON-P.H.S.; TUMOR NECROSIS FACTOR; VASCULAR RESISTANCE;

EID: 0024556554     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.1989.01410040055012     Document Type: Article

References (29)

1. Vogel SN, Moore RN, Sipe JD, et al: BCG-induced enhancement of endotoxin sensitivity in C3H/HeJ mice. J Immunol 1980;124:2004-2009.
2. Cerami A, Ikeda Y, Le Trang N, et al: Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin (tumor necrosis factor). Immunol Lett 1985;11:173-179.
3. Torti FM, Dievkmann B, Beutler B, et al: A macrophage factor inhibits adipocyte gene expression: An in vitro model of cachexia. Science 1985;229:867-869.
4. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-474.
5. Tracey KJ, Lowry SF, Fahey TJ, et al: Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987;164:415-422.
6. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-871.
7. Seigel JH, Cerra FB, Coleman B, et al: Physiologic and metabolic correlations in human sepsis. Surgery 1979;86:163-193.
8. Schirmer WJ, Townsend MC, Schirmer JM, et al: Galactose elimination kinetics in sepsis: Correlations of hepatic blood flow with function. Arch Surg 1987;122:349-354.
9. Townsend MC, Hampton WW, Haybron DM, et al: Effective organ blood flow and bioenergy status in murine peritonitis. Surgery 1986;100:205-213.
10. Isoyama T, Soto T, Tanaka J, et al: Measurement of cardiac output in small animals by a thermodilution method. J Surg Res 1982;33:153-164.
11. Schirmer WJ, Townsend MC, Schirmer JM, et al: Galactose clearance as an estimate of effective hepatic blood flow: Validation and limitations. J Surg Res 1987;41:543-556.
12. Henderson JM, Fales FW: Continuous flow fluorometry of low galactose concentrations in blood or plasma. Clin Chem 1983;26:129-132.
13. Smith HW: Measurement of renal clearances, in Smith HW (ed): Principles of Renal Physiology. New York, Oxford University Press Inc, 1956, appendix S.
14. Carrico CJ, Meakins JL, Marshall JC, et al: Multiple-organ-failure syndrome. Arch Surg 1986;121:196-208.
15. Dinarello CA: Interleukin-1. Rev Infect Dis 1984;6:951-984.
16. Remick DG, Kunkel RG, Larrick JW, et al: Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987;56:583-590.
17. Beutler B, Mahoney J, Le Trang N, et al: Purification of cachectin, a lipoprotein lipase suppressing hormone secreted by endotoxin-induced raw 264.7 cells. J Exp Med 1985;161:984-995.
18. Beutler B, Milsark IW, Cerami A: Cachectin/tumor necrosis factor. J Immunol 1985;135:3972-3979.
19. Hampton WW, Townsend MC, Haybron MC, et al: Effective hepatic blood flow and bioenergy status in murine peritonitis. J Surg Res 1987;42:33-38.
20. Asher EF, Rowe RL, Garrison RN, et al: Experimental bacteremia and nutrient hepatic blood flow. Circ Shock 1986;20:43-49.
21. Machiedo GW, Hurd T, Rush BF, et al: Temporal relationship of hepatocellular dysfunction and ischemia in sepsis. Arch Surg 1988;123:424-427.
22. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;137:1735-1742.
23. Schirmer WJ, Schirmer JM, Naff GB, et al: Systemic complement activation produces hemodynamic changes characteristic of sepsis. Arch Surg 1988;123:316-321.
24. Schirmer WJ, Schirmer JM, Naff GB, et al: Visceral perfusion abnormalities following complement activation: Clues to the mediators of organ ischemia in trauma and sepsis. Am Surg 1988;54:687-692.
25. Pohlman TH, Stanness KA, Beatty PG, et al: An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin-1, and tumor necrosis factor increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol 1986;136:4548-4553.
26. Djeu JY, Blanchard DK, Halkias D, et al: Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: Activation by interferon-gamma and tumor necrosis factor. J Immunol 1986;137:2980-2984.
27. Marshall JC, Christou NV, Horn R, et al: The microbiology of multiple organ failure: The proximal gastrointestinal tract as an occult reservoir for pathogens. Arch Surg 1988;123:309-315.
28. Deitch EA, Bridges W, Baker J, et al: Hemorrhagic shock–induced bacterial translocation is reduced by blocking xanthine-oxidase mediated activity. Surgery 1988;104:191-198.
29. Michie H. Spriggs D, Revhaug A, et al: Does tumor necrosis factor mediate the metabolic responses to septicemia/endotoxemia in humans? Surgery 1988;104:280-286.